ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease and certain infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.  Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

Type
Public
HQ
Ramsey, US
Founded
2004
Size (employees)
92 (est)
ADMA Biologics was founded in 2004 and is headquartered in Ramsey, US
Report incorrect company information

Key People/Management at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Director
Dov Goldstein

Dov Goldstein

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman

ADMA Biologics Office Locations

ADMA Biologics has an office in Ramsey and Boca Raton
Ramsey, US (HQ)
465 NJ-17
Boca Raton, US
5800 Park of Commerce Blvd
Show all (2)
Report incorrect company information

ADMA Biologics Financials and Metrics

ADMA Biologics Financials

ADMA Biologics's revenue was reported to be $10.66 m in FY, 2016 which is a 48.5% increase from the previous period.
USD

Revenue (Q3, 2017)

4.7 m

Net income (Q3, 2017)

(15.2 m)

EBIT (Q3, 2017)

(14.4 m)

Market capitalization (5-Feb-2018)

315.9 m

Cash (2-Feb-2018)

13.6 m

EV

316.9 m
ADMA Biologics's current market capitalization is $315.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

3.1 m5.9 m7.2 m10.7 m

Revenue growth, %

93%21%49%

General and administrative expense

8.5 m

R&D expense

7.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.1 m1.6 m1.5 m1.4 m1.5 m1.3 m1.9 m2.1 m2.3 m2.9 m2.6 m3.4 m4.7 m

General and administrative expense

845.3 k1.1 m1.5 m1 m1.3 m1.4 m2.1 m1.7 m1.7 m1.8 m4.3 m4.4 m

R&D expense

1.4 m4.3 m1.8 m1.5 m1.4 m1.5 m2.1 m2 m3.4 m1.7 m1.2 m1.4 m

Operating expense total

3.6 m7.2 m5.1 m4.4 m4.7 m4.8 m6.5 m6.3 m7.8 m6.7 m8.6 m11.8 m19.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

26.1 m17.2 m10.4 m9.9 m

Accounts Receivable

384 k924.5 k1 m

Inventories

1.7 m1.7 m3.4 m5 m

Current Assets

31.1 m24.1 m21.3 m21.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

5.4 m26.5 m17.9 m14 m16.6 m7.8 m9.2 m8.9 m12.5 m7.9 m8.5 m25.6 m13.6 m

Accounts Receivable

335.1 k484.4 k803.5 k562.2 k351.4 k522.5 k1.2 m944 k826.7 k1.3 m839.9 k2.3 m1.5 m

Inventories

1.2 m984.5 k1.1 m1.5 m1.9 m2.5 m2.8 m4 m4.2 m4.6 m5.3 m13.2 m13.4 m

Current Assets

7.1 m30.8 m26.5 m22.6 m31 m27.1 m25.2 m17.4 m29.5 m25.4 m15.7 m44.3 m31.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)

Depreciation and Amortization

247.9 k469.8 k469.6 k

Inventories

1.7 m(39.7 k)(1.7 m)(1.6 m)

Accounts Payable

2.7 m(937.8 k)308.7 k476.8 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(2.7 m)(5.9 m)(4 m)(3.4 m)(3.6 m)(4.7 m)(5.1 m)(4.6 m)(6 m)(4.3 m)(6.5 m)(15.2 m)

Inventories

1.1 m1.5 m1.9 m2.5 m2.8 m4 m4.2 m4.6 m5.3 m13.4 m

Accounts Payable

2.3 m2.4 m1.8 m1.6 m2.2 m2.5 m3.3 m2.8 m3.9 m9.2 m
USDY, 2017

EV/EBIT

-22 x

Revenue/Employee

51.4 k

Debt/Equity

1.1 x

Debt/Assets

0.2 x

Financial Leverage

5.6 x
Show all financial metrics
Report incorrect company information